Coronary artery bypass surgery postoperative antiplatelet therapy
|
Coronary Artery Bypass Surgery Microchapters | |
|
Pathophysiology | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Perioperative Monitoring | |
|
Surgical Procedure | |
|
Special Scenarios | |
|
Coronary artery bypass surgery postoperative antiplatelet therapy On the Web | |
|
FDA on Coronary artery bypass surgery postoperative antiplatelet therapy | |
|
CDC on Coronary artery bypass surgery postoperative antiplatelet therapy | |
|
Coronary artery bypass surgery postoperative antiplatelet therapy in the news | |
|
Blogs on Coronary artery bypass surgery postoperative antiplatelet therapy|- |
|
|
Directions to Hospitals Performing Coronary artery bypass surgery postoperative antiplatelet therapy | |
|
Risk calculators for Coronary artery bypass surgery postoperative antiplatelet therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]
Postoperative Antiplatelet Therapy (DO NOT EDIT)[1]
| Class I |
| "1. If aspirin (100 mg to 325 mg daily) was not initiated preoperatively, it should be initiated within 6 hours postoperatively and then continued indefinitely to reduce the occurrence of saphenous vein graft closure and adverse cardiovascular events.[2][3][4] (Level of Evidence: A)" |
| Class IIa |
| "1. For patients undergoing CABG, clopidogrel 75 mg daily is a reasonable alternative in patients who are intolerant of or allergic to aspirin. (Level of Evidence: C)" |
Guidelines Resources
- 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[1]
References
- ↑ 1.0 1.1 1.2 Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.
- ↑ Mangano DT (2002). "Aspirin and mortality from coronary bypass surgery". The New England Journal of Medicine. 347 (17): 1309–17. doi:10.1056/NEJMoa020798. PMID 12397188. Retrieved 2011-12-14. Unknown parameter
|month=ignored (help) - ↑ Sethi GK, Copeland JG, Goldman S, Moritz T, Zadina K, Henderson WG (1990). "Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy". Journal of the American College of Cardiology. 15 (1): 15–20. PMID 2404046. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients". BMJ (Clinical Research Ed.). 324 (7329): 71–86. 2002. PMC 64503. PMID 11786451. Retrieved 2011-12-14. Unknown parameter
|month=ignored (help)